Pfizer: Schizophrenia trials
The registry lists 35 Schizophrenia studies with Pfizer as lead sponsor. 0 are open to participants now and 6 have results posted.
Phase 1 19Phase 2 10Phase 3 4Phase 4 1No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study To Examine Safety, Pharmacokinetics, And Pharmacodynamic Of Pf 06412562 In Subjects With SchizophreniaCompletedNCT02418819Phase 1Results posted
- An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of SchizophreniaTerminatedNCT01939548Phase 2Results posted
- A Study To Examine The Safety, Tolerability And Pharmacokinetics Of PF-02545920 In Psychiatrically Stable Subjects With SchizophreniaCompletedNCT01829048Phase 1Results posted
- An Inpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Treatment Of Acute Exacerbation Of SchizophreniaCompletedNCT01175135Phase 2Results posted
- Double Blind, Randomized, 3 Week Inpatient Study To Evaluate The Safety & Efficacy Of PF-02545920 Compared With PlaceboTerminatedNCT00570063Phase 2Results posted
- Study Evaluating Vabicaserin in Subjects With SchizophreniaCompletedNCT00563706Phase 2Results posted
- A Study to Assess the Relative Bioavailability of a Modified-Release Formulation of PF-05180999CompletedNCT01530529Phase 1
- A Study Of The Safety, Tolerability And Pharmacokinetics Of Single Doses Of PF-05180999 In Healthy AdultsCompletedNCT01429740Phase 1
- Study Evaluating The Safety and Tolerability of HTC-867 in Healthy Japanese SubjectsCompletedNCT01268124Phase 1
- Pharmacokinetics, Safety and Tolerability Study of PF-03463275 in Healthy Male Japanese and Western SubjectsCompletedNCT01159626Phase 1
- A Study Of PF-03463275 As Add-On Therapy In Outpatients With Persistent Negative Symptoms Of SchizophreniaTerminatedNCT00977522Phase 2
- Study Evaluating the Effects of Multiple Doses of NSA-789 in Subjects With Schizophrenia or Schizoaffective DisorderWithdrawnNCT00892021Phase 1
- Study Evaluating HTC-867 in Healthy Young and Elderly SubjectsTerminatedNCT00827489Phase 1
- Multiple Dose Study Evaluating the Safety and Tolerability of NSA-789CompletedNCT00795730Phase 1
- Study Evaluating The Effects Of Single Oral Doses Of NSA-789 On Auditory P50 Suppression In Schizophrenic PatientsWithdrawnNCT00781794Phase 1
- Study Evaluating Safety and Tolerability of Vabicaserin in Patients With Sudden Worsening of SchizophreniaWithdrawnNCT00768612Phase 2
- A 6-Week Multicenter Trial Of Varenicline Tartrate For Cognitive Impairment In Subjects With SchizophreniaWithdrawnNCT00743847Phase 2
- Efficacy and Safety of Celecoxib as Add-on Therapy to Risperidone Versus Risperidone Alone in Patients With SchizophreniaCompletedNCT00639483Phase 2
- Study Evaluating Multiple Ascending Dose in Schizophrenia PatientsTerminatedNCT00620568Phase 1
- Study Evaluating Safety and Tolerability of Ascending Multiple Dose of SLV-313 in Schizophrenia PatientsTerminatedNCT00581243Phase 1
- Dose-response Study to Evaluate Safety, Efficacy, and Pharmacokinetics of PF-00217830 Compared With Placebo in Acute Exacerbation of SchizophreniaCompletedNCT00580125Phase 2
- A Study Of Adjunctive Treatment Of Cognitive Deficits In SchizophreniaCompletedNCT00567203Phase 1
- Study Comparing Bioavailability of Oral Formulations of VabicaserinCompletedNCT00541996Phase 1
- Study Evaluating the Safety and Tolerability of SCA-136 in Healthy Japanese Male SubjectsCompletedNCT00505973Phase 1
- Study Investigating the Safety and Tolerability of Multiple Doses of PF-02545920 in Subjects With SchizophreniaCompletedNCT00463372Phase 1
- Study Evaluating the Safety and Tolerability of SCA-136 in Healthy Japanese and Non-Japanese Female SubjectsCompletedNCT00458107Phase 1
- Safety, PK and PD Study in Healthy Male Japanese SubjectsCompletedNCT00447941Phase 1
- Large Simple Trial (LST) Of Cardiovascular Safety Of Ziprasidone And Olanzapine- (Zodiac)CompletedNCT00418171Phase 4
- Study Comparing the Affect of Bifeprunox Vs Olanzapine on Weight During the Treatment of Outpatients With Schizophrenia.CompletedNCT00380224Phase 3
- Study Comparing Bifeprunox to Risperidone in Treatment of Outpatients With Schizophrenia With Weight as Primary EndpointTerminatedNCT00366704Phase 3
- Study Evaluating Bifeprunox in Patients With Schizophrenia.TerminatedNCT00366327Phase 3
- Open Label Extension Study of BifeprunoxCompletedNCT00366171Phase 3
- Study Evaluating SCA-136 in Subjects With Acute Exacerbations of SchizophreniaCompletedNCT00265551Phase 2
- Study To Assess Differential Sensitivity Of 2 Spatial Working Memory Tests In Schizophrenics Treated With RisperidoneCompletedNCT00174200Not applicable
- A First In Human Study Of PF-00184562 In Healthy VolunteersCompletedNCT00150215Phase 1